Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 3, 2008, Pages 893-894

  Chen, Chun Hsin ^a   Huang, Ming Chyi ^b   Lu, Mong Liang ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; PROLACTIN; SULPIRIDE; TRIHEXYPHENIDYL; VENLAFAXINE; ZOLPIDEM;

CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFECT; HUMAN; HYPERLEPTINEMIA; HYPERPROLACTINEMIA; LETTER; MALE; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; HUMANS; HYPERPROLACTINEMIA; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; SULPIRIDE;

EID: 40049086110     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.11.007     Document Type: Letter

References (13)

1. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 (2002) 381-389
2. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
3. Kinon B.J., Ahl J., Liu-Seifert H., and Maguire G.A. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 31 (2006) 577-588
4. Knegtering H., van der Moolen A.E., Castelein S., Kluiter H., and van den Bosch R.J. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology 28 Suppl 2 (2003) 109-123
5. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288 (1999) 774-781
6. Lee B.H., Kim Y.K., and Park S.H. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 714-717
7. Lin S.K., and Chen C.K. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry 67 (2006) 1307
8. McGahuey C.A., Gelenberg A.J., Laukes C.A., Moreno F.A., Delgado P.L., McKnight K.M., et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26 (2000) 25-40
9. Meston C.M., and Frohlich P.F. The neurobiology of sexual function. Arch Gen Psychiatry 57 11 (2000) 1012-1030
10. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60 (2003) 681-690
11. Ricci E., Parazzini F., Mirone V., Imbimbo C., Palmieri A., Bortolotti A., et al. Current drug use as risk factor for erectile dysfunction: results from an Italian epidemiological study. Int J Impot Res 15 (2003) 221-224
12. Thase M.E., Clayton A.H., Haight B.R., Thompson A.H., Modell J.G., and Johnston J.A. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 26 (2006) 482-488
13. Wahl R., and Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 162 (2005) 1542-1543